| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS44013062 | HTLV-1 | ENSG00000101180.17 | protein_coding | HRH3 | No | No | 11255 | Q9Y5N1 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | HRH3 |
|---|---|
| DrugBank ID | DB06698 |
| Drug Name | Betahistine |
| Target ID | BE0000968 |
| UniProt ID | Q9Y5N1 |
| Regulation Type | antagonist |
| PubMed IDs | 18447604; 11700150; 20530654; 19300572 |
| Citations | Barak N: Betahistine: what's new on the agenda? Expert Opin Investig Drugs. 2008 May;17(5):795-804. doi: 10.1517/13543784.17.5.795 .@@Lacour M, Sterkers O: Histamine and betahistine in the treatment of vertigo: elucidation of mechanisms of action. CNS Drugs. 2001;15(11):853-70.@@Gbahou F, Davenas E, Morisset S, Arrang JM: Effects of betahistine at histamine H3 receptors: mixed inverse agonism/agonism in vitro and partial inverse agonism in vivo. J Pharmacol Exp Ther. 2010 Sep 1;334(3):945-54. doi: 10.1124/jpet.110.168633. Epub 2010 Jun 8.@@Lacour M, van de Heyning PH, Novotny M, Tighilet B: Betahistine in the treatment of Meniere's disease. Neuropsychiatr Dis Treat. 2007 Aug;3(4):429-40. |
| Groups | Approved; Investigational |
| Direct Classification | Aralkylamines |
| SMILES | CNCCC1=CC=CC=N1 |
| Pathways | Betahistine H1-Antihistamine Action |
| PharmGKB | PA165958372 |
| ChEMBL | CHEMBL24441 |
